We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
We expect investors to focus on the updates related to Entera Bio, Ltd. (ENTX - Free Report) pipeline candidates when it reports fourth-quarter 2022 results (expected next month).
Shares of Entera Bio have declined 57.4% in the past year compared with the industry’s decline of 7.4%.
Image Source: Zacks Investment Research
ENTX’s earnings surpassed expectations in all the trailing four quarters, the average positive surprise being 89.07%. In the last reported quarter, Entera Bio reported a positive earnings surprise of 31.25%.
Let us see how things have shaped up for the quarter to be reported.
Factors to Consider
In the absence of a marketed product, Entera Bio is expected to provide updates on its pipeline candidates,mainly EB613 and EB612, for the treatment of osteoporosis and hypoparathyroidism, respectively.
In October, Entera reached an agreement with the FDA for its pivotal study of its lead candidate, EB613, to treat osteoporosis. Per the terms of the agreement, Entera Bio has been authorized to submit a new drug application based on a single pivotal phase III study for EB613, abiding by the 505(b)(2) regulatory clause.
Agreement about the primary endpoint benchmark was also reached. The FDA agreed that the total hip bone mineral density, excluding fracture, would suffice as the primary endpoint for the study. The FDA has permitted Entera to use the same post-menopausal osteoporosis patient population who previously responded well in the phase II study of EB613. The phase II study results were reported back in 2021.
The agreement with the FDA was made based on the phase II study of EB613 tablets which showed a strong, statistically significant correlation between mean blood level and the dose of EB613 taken.
After the agreement, Entera recently announced that the FDA has accepted a Type D meeting review to affirm the study design, responding by Mar 30, 2023.
Enrollment for the phase III study is set to begin in the second half of 2023.
Enterera’s other lead product candidate, EB612, is currently under phase II study for the treatment of hypoparathyroidism. Since publishing the pilot 4-month phase II study data on EB612, back in 2021, the company has been working on an optimized formulation for EB612 which may enable twice-a-day administration (versus the previous 4 times a day). This formulation is based on new intellectual property and is expected to reduce daily dosing for hypoparathyroidism.
Entera anticipates the commencement of a PK study in the first half of 2023 for the new formulation of EB612.
The company is expected to earn most of its revenues from pre-clinical research and development services provided to Amgen as a part of its ongoing license agreement in the to-be-reported quarter.
Research and development expenses are also expected to go down due to the completion of the company’s phase II study for EB613 in September 2021.
Earnings Whisper
Our proven model does not conclusively predict an earnings beat for Entera Bio this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Earnings ESP: Entera Bio has an Earnings ESP of 0.00% as the Zacks Consensus Estimate and the Most Accurate Estimate both stand at a loss of 12 cents.
Here are some stocks in the same industry that have the right combination of elements to beat on earnings this time around:
BeiGene, Ltd. (BGNE - Free Report) has an Earnings ESP of +4.19% and a Zacks Rank #2.
BGNE’s stock has increased by 9% in the past year. BGNE beat earnings estimates in one out of the last four quarters. It has a loss surprise of 21.98% on average.
Allogene Therapeutics, Inc. (ALLO - Free Report) has an Earnings ESP of +25.70% and a Zacks Rank #2.
ALLO’s stock declined 22.6% in the past year. ALLO beat earnings expectations in all the trailing four quarters. The average surprise was 9.44%.
Aligos Therapeutics, Inc. (ALGS - Free Report) has an Earnings ESP of +4.08% and a Zacks Rank #3.
ALGS’ stock declined 29.8% in the past year. ALGS beat earnings expectations in two of the trailing four quarters. The average surprise was 4%.
Image: Bigstock
Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?
We expect investors to focus on the updates related to Entera Bio, Ltd. (ENTX - Free Report) pipeline candidates when it reports fourth-quarter 2022 results (expected next month).
Shares of Entera Bio have declined 57.4% in the past year compared with the industry’s decline of 7.4%.
Image Source: Zacks Investment Research
ENTX’s earnings surpassed expectations in all the trailing four quarters, the average positive surprise being 89.07%. In the last reported quarter, Entera Bio reported a positive earnings surprise of 31.25%.
Let us see how things have shaped up for the quarter to be reported.
Factors to Consider
In the absence of a marketed product, Entera Bio is expected to provide updates on its pipeline candidates,mainly EB613 and EB612, for the treatment of osteoporosis and hypoparathyroidism, respectively.
In October, Entera reached an agreement with the FDA for its pivotal study of its lead candidate, EB613, to treat osteoporosis. Per the terms of the agreement, Entera Bio has been authorized to submit a new drug application based on a single pivotal phase III study for EB613, abiding by the 505(b)(2) regulatory clause.
Agreement about the primary endpoint benchmark was also reached. The FDA agreed that the total hip bone mineral density, excluding fracture, would suffice as the primary endpoint for the study. The FDA has permitted Entera to use the same post-menopausal osteoporosis patient population who previously responded well in the phase II study of EB613. The phase II study results were reported back in 2021.
The agreement with the FDA was made based on the phase II study of EB613 tablets which showed a strong, statistically significant correlation between mean blood level and the dose of EB613 taken.
After the agreement, Entera recently announced that the FDA has accepted a Type D meeting review to affirm the study design, responding by Mar 30, 2023.
Enrollment for the phase III study is set to begin in the second half of 2023.
Enterera’s other lead product candidate, EB612, is currently under phase II study for the treatment of hypoparathyroidism. Since publishing the pilot 4-month phase II study data on EB612, back in 2021, the company has been working on an optimized formulation for EB612 which may enable twice-a-day administration (versus the previous 4 times a day). This formulation is based on new intellectual property and is expected to reduce daily dosing for hypoparathyroidism.
Entera anticipates the commencement of a PK study in the first half of 2023 for the new formulation of EB612.
The company is expected to earn most of its revenues from pre-clinical research and development services provided to Amgen as a part of its ongoing license agreement in the to-be-reported quarter.
Research and development expenses are also expected to go down due to the completion of the company’s phase II study for EB613 in September 2021.
Earnings Whisper
Our proven model does not conclusively predict an earnings beat for Entera Bio this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Earnings ESP: Entera Bio has an Earnings ESP of 0.00% as the Zacks Consensus Estimate and the Most Accurate Estimate both stand at a loss of 12 cents.
Entera Bio Ltd. Price, Consensus and EPS Surprise
Entera Bio Ltd. price-consensus-eps-surprise-chart | Entera Bio Ltd. Quote
Zacks Rank: Entera Bio currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Here are some stocks in the same industry that have the right combination of elements to beat on earnings this time around:
BeiGene, Ltd. (BGNE - Free Report) has an Earnings ESP of +4.19% and a Zacks Rank #2.
BGNE’s stock has increased by 9% in the past year. BGNE beat earnings estimates in one out of the last four quarters. It has a loss surprise of 21.98% on average.
Allogene Therapeutics, Inc. (ALLO - Free Report) has an Earnings ESP of +25.70% and a Zacks Rank #2.
ALLO’s stock declined 22.6% in the past year. ALLO beat earnings expectations in all the trailing four quarters. The average surprise was 9.44%.
Aligos Therapeutics, Inc. (ALGS - Free Report) has an Earnings ESP of +4.08% and a Zacks Rank #3.
ALGS’ stock declined 29.8% in the past year. ALGS beat earnings expectations in two of the trailing four quarters. The average surprise was 4%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.